ストックスクリーナーアプリを入手
0.861
4.31%
-0.0388
アフターアワーズ：
.88
0.019
+2.21%
前日終値:
$0.8998
開ける：
$0.8611
24時間の取引高:
155.94K
Relative Volume:
0.78
時価総額：
$66.42M
収益：
$8.23M
当期純損益:
$-32.49M
株価収益率:
-1.6245
EPS:
-0.53
ネットキャッシュフロー:
$-19.91M
1週間 パフォーマンス:
-9.37%
1か月 パフォーマンス:
+7.62%
6か月 パフォーマンス:
-40.62%
1年 パフォーマンス:
-35.26%
1日の値動き範囲:
$0.8446
$0.90
1週間の範囲:
$0.8446
$1.00
52週間の値動き範囲:
$0.7737
$1.65
Clearside Biomedical Inc Stock (CLSD) Company Profile
名前
Clearside Biomedical Inc
セクター
電話
678-270-3631
住所
900 NORTH POINT PARKWAY, ALPHARETTA, GA
CLSD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLSD
Clearside Biomedical Inc
|
0.861 | 66.42M | 8.23M | -32.49M | -19.91M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-21 | 開始されました | Chardan Capital Markets | Buy |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2021-12-15 | 再開されました | Wedbush | Outperform |
| 2021-07-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-13 | 開始されました | ROTH Capital | Buy |
| 2019-08-09 | ダウングレード | Needham | Buy → Hold |
| 2018-11-05 | ダウングレード | Cowen | Outperform → Market Perform |
| 2018-11-05 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2018-11-05 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-06 | 繰り返されました | Needham | Buy |
| 2017-05-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2017-02-24 | 開始されました | JP Morgan | Overweight |
| 2016-11-10 | 繰り返されました | Needham | Buy |
| 2016-10-24 | 繰り返されました | Stifel | Buy |
すべてを表示
Clearside Biomedical Inc (CLSD) 最新ニュース
HC Wainwright Analysts Lift Earnings Estimates for CLSD - Defense World
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Key Strategic Updates Expected: Clearside Biomedical CEO Takes Stage at Major Healthcare Conference - Stock Titan
Clearside Biomedical’s (CLSD) Buy Rating Reaffirmed at HC Wainwright - Defense World
Clearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edge - Investing.com Australia
Clearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edge By Investing.com - Investing.com South Africa
Clearside outlines pivotal Phase 3 plans for CLS-AX in wet AMD - MSN
Clearside Biomedical (NASDAQ:CLSD) Earns “Buy” Rating from Chardan Capital - Defense World
Needham & Company LLC Has Lowered Expectations for Clearside Biomedical (NASDAQ:CLSD) Stock Price - Defense World
Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations - Yahoo Finance
JMP reiterates Clearside Biomedical stock with $5 target By Investing.com - Investing.com Canada
Clearside Biomedical’s Positive Earnings Call Highlights Progress and Challenges - TipRanks
Stifel maintains Clearside Biomedical buy rating, $8 target By Investing.com - Investing.com UK
Clearside Biomedical (CLSD) Prepares for Phase 3 Trials, Seeks F - GuruFocus
Clearside Biomedical Reports Net Loss for Fourth Quarter and Full Year 2024 - VisionMonday.com
Clearside Biomedical Reports 2024 Earnings and Strategic Progress - TipRanks
Earnings call transcript: Clearside Biomedical Q4 2024 revenue beats forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Clearside Biomedical Q4 2024 revenue beats forecast - Investing.com India
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings: EPS Matches Es - GuruFocus
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Clearside Biomedical Reports 2024 Financial Results and Updates - TipRanks
Clearside Biomedical Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Clearside Biomedical earnings matched, revenue topped estimates - Investing.com
CLEARSIDE BIOMEDICAL Earnings Results: $CLSD Reports Quarterly Earnings - Nasdaq
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Clearside Reports 95% Revenue Decline, But Secures Critical FDA Agreement for Phase 3 Trial - Stock Titan
Exploring Clearside Biomedical's Earnings Expectations - Benzinga
Clearside Biomedical Announces Six Abstracts Accepted for - GlobeNewswire
Game-Changing Eye Treatment Data: Clearside to Present Phase 2b Results at ARVO 2025 - Stock Titan
Clearside Biomedical Presents Comparative Data on CLS-AX for Wet AMD at 2025 Wet AMD & Diabetic Eye Disease Summit - Nasdaq
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet - GlobeNewswire
Clearside's Revolutionary Eye Treatment Platform Targets $12B Wet AMD Market After FDA Green Light - StockTitan
Clearside Biomedical (NASDAQ:CLSD) Downgraded to Sell Rating by StockNews.com - Defense World
Clearside Biomedical to Report Fourth Quarter and Full Year - GlobeNewswire
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 - The Manila Times
Clearside Biomedical, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025 - Nasdaq
Clearside Biomedical Q4 Earnings: Key Date Announced for Critical Year-End Financial Results - StockTitan
Clearside Biomedical (CLSD) Projected to Post Earnings on Tuesday - Defense World
HC Wainwright Reiterates “Buy” Rating for Clearside Biomedical (NASDAQ:CLSD) - Defense World
Clearside Biomedical, Inc. to Host Earnings Call - ACCESS Newswire
Clearside Biomedical Announces Successful End-of-Phase 2 - GlobeNewswire
Buy Rating on Clearside Biomedical: Strategic Advancements in CLS-AX Program for wAMD - TipRanks
Promising Potential of Clearside Biomedical’s CLS-AX Treatment Justifies Buy Rating - TipRanks
Clearside Biomedical (CLSD) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Clearside Biomedical announces successful End-of-Phase 2 meeting for CLS-AX - TipRanks
Can This New Wet AMD Treatment Challenge the $12B Market? FDA Says Yes to Phase 3 - StockTitan
Clearside Biomedical stock hits 52-week low at $0.79 - Investing.com
Clearside Biomedical Inc. Revolutionizes Panuveitis Treatment With Innovative Xipere Product: Key Trend in ... - WhaTech
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of “Buy” by Brokerages - Defense World
Clearside Biomedical Inc (CLSD) 財務データ
収益
当期純利益
現金流量
EPS
Clearside Biomedical Inc (CLSD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Chong Ngai Hang Victor | Chief Medical Officer |
Nov 01 '24 |
Buy |
1.00 |
36,500 |
36,500 |
100,000 |
| Chong Ngai Hang Victor | Chief Medical Officer |
Jun 24 '24 |
Buy |
1.06 |
23,500 |
24,910 |
63,500 |
| YERXA BENJAMIN R | Director |
May 15 '24 |
Buy |
1.31 |
7,813 |
10,235 |
17,957 |
| Gibney Anthony S | Director |
Apr 18 '24 |
Buy |
1.30 |
93,290 |
121,277 |
100,000 |
| Gibney Anthony S | Director |
Apr 17 '24 |
Buy |
1.25 |
6,710 |
8,388 |
6,710 |
3.01%
大文字化:
|
ボリューム (24 時間):